PURPOSE: Tyrosine kinase inhibitors (TKI) that target MET signaling have shown promise in various types of cancer, including lung cancer. Combination strategies have been proposed and developed to increase their therapeutic index. Based on preclinical synergy between inhibition of MET and topoisomerase I, a phase I study was designed to explore the combination of topotecan with the MET TKI tivantinib. METHODS: Eligible patients with advanced solid malignancies for which there was no known effective treatment received topotecan at doses of 1.0-1.5 mg/m2/day for five consecutive days in 21-day cycles with continuous, oral tivantinib given at escalating doses of 120-360 mg orally twice daily. Pharmacokinetic analyses of tivantinib were included. Circulating tumor cells (CTC) were collected serially to identify peripheral changes in MET phosphorylation. RESULTS: The trial included 18 patients, 17 of whom received treatment. At the planned doses, the combination of topotecan and tivantinib was not tolerable due to thrombocytopenia and neutropenia. The addition of G-CSF to attenuate neutropenia did not improve tolerability. Greater tivantinib exposure, assessed through pharmacokinetic analysis, was associated with greater toxicity. No responses were seen. MET phosphorylation was feasible in CTC, but no changes were seen with therapy. CONCLUSIONS: The combination of topotecan and oral tivantinib was not tolerable in this patient population.
PURPOSE: Tyrosine kinase inhibitors (TKI) that target MET signaling have shown promise in various types of cancer, including lung cancer. Combination strategies have been proposed and developed to increase their therapeutic index. Based on preclinical synergy between inhibition of MET and topoisomerase I, a phase I study was designed to explore the combination of topotecan with the MET TKI tivantinib. METHODS: Eligible patients with advanced solid malignancies for which there was no known effective treatment received topotecan at doses of 1.0-1.5 mg/m2/day for five consecutive days in 21-day cycles with continuous, oral tivantinib given at escalating doses of 120-360 mg orally twice daily. Pharmacokinetic analyses of tivantinib were included. Circulating tumor cells (CTC) were collected serially to identify peripheral changes in MET phosphorylation. RESULTS: The trial included 18 patients, 17 of whom received treatment. At the planned doses, the combination of topotecan and tivantinib was not tolerable due to thrombocytopenia and neutropenia. The addition of G-CSF to attenuate neutropenia did not improve tolerability. Greater tivantinib exposure, assessed through pharmacokinetic analysis, was associated with greater toxicity. No responses were seen. MET phosphorylation was feasible in CTC, but no changes were seen with therapy. CONCLUSIONS: The combination of topotecan and oral tivantinib was not tolerable in this patient population.
Entities:
Keywords:
ARQ-197; Circulating tumor cells; MET phosphorylation; Tivantinib; Topotecan
Authors: Christos E Kyriakopoulos; Amy M Braden; Jill M Kolesar; Jens C Eickhoff; Howard H Bailey; Jennifer Heideman; Glenn Liu; Kari B Wisinski Journal: Invest New Drugs Date: 2016-12-21 Impact factor: 3.850
Authors: Darren R Feldman; Lawrence H Einhorn; David I Quinn; Yohann Loriot; Johnathan K Joffe; David J Vaughn; Aude Fléchon; Julio Hajdenberg; Abdel-Baset Halim; Hamim Zahir; Robert J Motzer Journal: Invest New Drugs Date: 2013-02-17 Impact factor: 3.850
Authors: Lee S Rosen; Neil Senzer; Tarek Mekhail; Ram Ganapathi; Feng Chai; Ronald E Savage; Carol Waghorne; Giovanni Abbadessa; Brian Schwartz; Robert Dreicer Journal: Clin Cancer Res Date: 2011-10-05 Impact factor: 12.531
Authors: Antonio Calles; Nicholas Kwiatkowski; Bernard K Cammarata; Dalia Ercan; Nathanael S Gray; Pasi A Jänne Journal: Mol Oncol Date: 2014-08-29 Impact factor: 6.603
Authors: S Pant; M Saleh; J Bendell; J R Infante; S Jones; C D Kurkjian; K M Moore; J Kazakin; G Abbadessa; Y Wang; Y Chen; B Schwartz; L H Camacho Journal: Ann Oncol Date: 2014-04-15 Impact factor: 32.976
Authors: A Santoro; M Simonelli; C Rodriguez-Lope; P Zucali; L H Camacho; A Granito; N Senzer; L Rimassa; G Abbadessa; B Schwartz; M Lamar; R E Savage; J Bruix Journal: Br J Cancer Date: 2013-01-03 Impact factor: 7.640
Authors: William F Maguire; John C Schmitz; Jonas Scemama; Ken Czambel; Yan Lin; Anthony G Green; Shaoyu Wu; Huang Lin; Shannon Puhalla; John Rhee; Ronald Stoller; Hussein Tawbi; James J Lee; John J Wright; Jan H Beumer; Edward Chu; Leonard J Appleman Journal: Cancer Chemother Pharmacol Date: 2021-06-23 Impact factor: 3.288